Mind + Muscle

technical minds + legal muscle


dig deep

State Biosimilar Bills Pose New Threat to Budding Industry

  • 02.13.13
  • Jeff Overley
  • IP Law360

Timothy J. Shea, Jr. was quoted in an article that recently appeared in IP Law360. The article, entitled "State Biosimilar Bills Pose New Threat To Budding Industry", discusses proposed restrictions to patient access to generic medicine. Opponents of the state-level regulations claim that restrictions will harm the biosimilars industry and infringe upon federal regulations. The proposed bills would require pharmacists to notify doctors of substitutions, receive written consent from patients, and keep records of substitutions.

In response to the notification and consent requirements, Mr. Shea explained that the bills leave the false impression that substitutions for biosimilars are risky. "Anything that raises the specter that this product is not the same as the brand product, and moves you further away from the ease we see with generic drugs being substituted, can be an impediment," Mr. Shea said.

Subscribers of Law360 can access the full article here.

Related People

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.